The Central Drugs Standard Organisation (CDSCO) has granted approval for the first phase of clinical trials for a novel molecule intended to treat multiple autoimmune disorders. The molecule is being developed to address rheumatoid arthritis, ulcerative colitis, plaque psoriasis, and alopecia. Initial trials will focus on assessing safety and preliminary efficacy in a small group of patients. The CDSCO’s decision signifies a significant step forward in research targeting these conditions.
Sunday, September 14
